Berlin/ Boston, June 29, 2022 – Bayer AG revealed today the opening of its brand-new Research and Innovation Center at Kendall Square in Boston-Cambridge, Massachusetts (U.S.A.), broadening even more the business’s footprint into among the world’s most ingenious pharmaceutical research study and advancement places. Representing an overall $140M USD financial investment into the location, Bayer’s 62,100-square-foot structure homes a brand-new center of accuracy molecular oncology research study geared up with modern labs and workplaces for the advancement of unique targeted cancer treatments for clients. In addition, the center consists of a recently developed research study group concentrated on leveraging chemical biology methods to more move the business’s oncology drug advancement procedure.
“Our brand-new Bayer research study and development center at Kendall Square belongs to our technique to be at the leading edge of clinical discovery and advancement development for much better client health care,” stated Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division. “Being part of this distinct development community will support our groups in producing development developments for clients together with the professionals here.”
“Bayer has a growing neighborhood of first-rate innovators – from our internal professionals and partners such as Vividion, to our international network of scholastic and market partners, a lot of which lie right here in the Boston location,” stated Christian Rommel, Member of the Executive Committee of Bayer AG’s Pharmaceutical Division and Head of Research and Development at Bayer. “Our brand-new research study and development center in Kendall Square brings us closer to these partners, to fellow researchers and organizations that join us in our objective to keep pressing the limits of medical development with the function of bringing impactful health options to clients.”
“We have actually brought a variety of distinct oncology treatments to clients over the previous years,” stated Christine Roth, Member of the Executive Committee of Bayer’s Pharmaceutical Division and Head of the Oncology SBU at Bayer. “Our aspiration is to play a considerable function in the next wave of development developments in oncology. The opening of